Dova Pharmaceuticals Inc. filed for an IPO of up to $74.8 million of its common stock.
The company plans to apply for listing of its common stock on the Nasdaq Global Market under the symbol DOVA.
Dova plans to use the net proceeds from the offering to fund the commercialization of avatrombopag, a drug to treat low blood platelet count, if approved; to fund clinical trials of the drug for additional indications beyond its initial indication; as repayment to Eisai Co. Ltd. of a portion of obligations under the Eisai note; and the balance for other general corporate purposes, including general and administrative expenses and working capital.
The underwriters for the IPO include J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC.
Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.